FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2619328782> ?p ?o ?g. }

• W2619328782 endingPage "56879" @default.
• W2619328782 startingPage "56868" @default.
• W2619328782 abstract "// Juan Zhou 1, * , Tong Ren 1, * , Ying Li 2, * , Anran Cheng 3 , Wanyi Xie 3 , Lanxi Xu 3 , Lu Peng 3 , Jinbin Lin 3 , Lianxiang Lian 3 , Yong Diao 4 , Xin Jin 3 and Lichao Yang 3 1 Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China 2 Department of Pharmacy, Xiamen Medical College, Xiamen, China 3 Xiamen Key Laboratory of Chiral Drugs, Medical College, Xiamen University, Xiamen, China 4 School of Biomedical Sciences, Huaqiao University, Quanzhou, China * These authors have contributed equally to this work and should be considered co-first authors Correspondence to: Xin Jin, email: xinjin@xmu.edu.cn Lichao Yang, email: yanglc116@xmu.edu.cn Keywords: oleoylethanolamide, melanin, tyrosinase, α-melanocyte stimulating hormone, B16 mouse melanoma cell Received: January 17, 2017      Accepted: April 11, 2017      Published: May 23, 2017 ABSTRACT The present study aimed to examine the potential inhibitory activity of oleoylethanolamide (OEA) on α-melanocyte stimulating hormone (α-MSH)-stimulated melanogenesis and the molecular mechanism(s) involved in the process in B16 mouse melanoma cells. Our data demonstrated that OEA markedly inhibited melanin synthesis and tyrosinase activity in α-MSH-stimulated B16 cells. In addition, the expression of melanogenesis-related proteins, such as melanocortin-1 receptor (MC1R), microphthalmia-associated transcription factor (MITF), tyrosinase-related protein-1 (TRP-1) and tyrosinase, was suppressed in a concentration-dependent manner by OEA. In addition, OEA may suppress melanogenesis through a peroxisome proliferator-activated receptor α (PPARα)-independent pathway. Moreover, OEA activated ERK, Akt, p38 pathways and inhibits CREB pathway in α-MSH-stimulated B16 cells. The specific ERK inhibitor PD98059 partly blocked OEA-inhibited melanin synthesis and tyrosinase activity and partly abrogated the OEA-suppressed expression of melanogenic proteins. Furthermore, OEA presented remarkable inhibition on the body pigmentation in the zebrafish model system. Our findings demonstrated that OEA is an effective inhibitor of hyperpigmentation through activation of ERK, Akt and p38 pathways, inhibition of the CREB pathway, and subsequent down-regulation of MITF, TRP-1 and tyrosinase production." @default.
• W2619328782 created "2017-06-05" @default.
• W2619328782 creator A5003628992 @default.
• W2619328782 creator A5010415795 @default.
• W2619328782 creator A5012507632 @default.
• W2619328782 creator A5026440290 @default.
• W2619328782 creator A5043247288 @default.
• W2619328782 creator A5043717904 @default.
• W2619328782 creator A5060002817 @default.
• W2619328782 creator A5073324084 @default.
• W2619328782 creator A5077541525 @default.
• W2619328782 creator A5082211250 @default.
• W2619328782 creator A5083151071 @default.
• W2619328782 creator A5087827150 @default.
• W2619328782 date "2017-05-23" @default.
• W2619328782 modified "2023-09-22" @default.
• W2619328782 title "Oleoylethanolamide inhibits α-melanocyte stimulating hormone-stimulated melanogenesis via ERK, Akt and CREB signaling pathways in B16 melanoma cells" @default.
• W2619328782 cites W1495400959 @default.
• W2619328782 cites W1894931559 @default.
• W2619328782 cites W1968873996 @default.
• W2619328782 cites W1971239441 @default.
• W2619328782 cites W1977666051 @default.
• W2619328782 cites W1979077842 @default.
• W2619328782 cites W1979963836 @default.
• W2619328782 cites W1994362073 @default.
• W2619328782 cites W1998807836 @default.
• W2619328782 cites W2006037913 @default.
• W2619328782 cites W2014885544 @default.
• W2619328782 cites W2029912972 @default.
• W2619328782 cites W2030692510 @default.
• W2619328782 cites W2032431960 @default.
• W2619328782 cites W2032466268 @default.
• W2619328782 cites W2037455853 @default.
• W2619328782 cites W2044311798 @default.
• W2619328782 cites W2051655321 @default.
• W2619328782 cites W2053171479 @default.
• W2619328782 cites W2062767635 @default.
• W2619328782 cites W2067403983 @default.
• W2619328782 cites W2076137142 @default.
• W2619328782 cites W2076956498 @default.
• W2619328782 cites W2080373548 @default.
• W2619328782 cites W2086586398 @default.
• W2619328782 cites W2109825099 @default.
• W2619328782 cites W2110332748 @default.
• W2619328782 cites W2139802586 @default.
• W2619328782 cites W2146627961 @default.
• W2619328782 cites W2149250648 @default.
• W2619328782 cites W2155364136 @default.
• W2619328782 cites W2328529137 @default.
• W2619328782 cites W2531095143 @default.
• W2619328782 cites W2941336906 @default.
• W2619328782 doi "https://doi.org/10.18632/oncotarget.18097" @default.
• W2619328782 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5593609" @default.
• W2619328782 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28915638" @default.
• W2619328782 hasPublicationYear "2017" @default.
• W2619328782 type Work @default.
• W2619328782 sameAs 2619328782 @default.
• W2619328782 citedByCount "27" @default.
• W2619328782 countsByYear W26193287822017 @default.
• W2619328782 countsByYear W26193287822018 @default.
• W2619328782 countsByYear W26193287822019 @default.
• W2619328782 countsByYear W26193287822020 @default.
• W2619328782 countsByYear W26193287822021 @default.
• W2619328782 countsByYear W26193287822022 @default.
• W2619328782 countsByYear W26193287822023 @default.
• W2619328782 crossrefType "journal-article" @default.
• W2619328782 hasAuthorship W2619328782A5003628992 @default.
• W2619328782 hasAuthorship W2619328782A5010415795 @default.
• W2619328782 hasAuthorship W2619328782A5012507632 @default.
• W2619328782 hasAuthorship W2619328782A5026440290 @default.
• W2619328782 hasAuthorship W2619328782A5043247288 @default.
• W2619328782 hasAuthorship W2619328782A5043717904 @default.
• W2619328782 hasAuthorship W2619328782A5060002817 @default.
• W2619328782 hasAuthorship W2619328782A5073324084 @default.
• W2619328782 hasAuthorship W2619328782A5077541525 @default.
• W2619328782 hasAuthorship W2619328782A5082211250 @default.
• W2619328782 hasAuthorship W2619328782A5083151071 @default.
• W2619328782 hasAuthorship W2619328782A5087827150 @default.
• W2619328782 hasBestOaLocation W26193287821 @default.
• W2619328782 hasConcept C104317684 @default.
• W2619328782 hasConcept C107538193 @default.
• W2619328782 hasConcept C126322002 @default.
• W2619328782 hasConcept C127716648 @default.
• W2619328782 hasConcept C134018914 @default.
• W2619328782 hasConcept C1629964 @default.
• W2619328782 hasConcept C170493617 @default.
• W2619328782 hasConcept C177504595 @default.
• W2619328782 hasConcept C181199279 @default.
• W2619328782 hasConcept C182843373 @default.
• W2619328782 hasConcept C185592680 @default.
• W2619328782 hasConcept C55493867 @default.
• W2619328782 hasConcept C71924100 @default.
• W2619328782 hasConcept C86339819 @default.
• W2619328782 hasConcept C87554066 @default.
• W2619328782 hasConcept C98274493 @default.
• W2619328782 hasConceptScore W2619328782C104317684 @default.
• W2619328782 hasConceptScore W2619328782C107538193 @default.
• W2619328782 hasConceptScore W2619328782C126322002 @default.

• next